As COVID-19 vaccine guidance shifts, new data suggest vaccinated patients face no greater clot or death risk than with other respiratory infections.
|Articles|March 26, 2023
Vaccines, Variants, and More: COVID-19 Year in Review
Author(s)Lauren Biscaldi, MS
From variants to vaccines, much has changed in the COVID-19 landscape.
Advertisement
Jacinda C. Abdul-Mutakabbir, PharmD, MPH, AAHIVP, Assistant Professor of Clinical Pharmacy at the University of California, San Diego, sat down with Drug Topics at the APhA 2023 Annual Meeting to review some the most crucial COVID-19 updates from 2022.
Advertisement
Related to this article
New survey data add to the evidence regarding the safe and effective route of administering both COVID-19 and flu vaccines simultaneously.
Researchers provide an update on the adverse events of special interest following patients who received 2024–2025 Pfizer-BioNTech COVID-19 vaccination.
From expert sources and recent data updates to a look at cases amid the ongoing respiratory virus season, this is an updated look at 2026 measles outbreaks in the US.
Phase 2 trial results for the investigational vaccine were presented at IDWeek 2026 in Washington, DC, as the phase 3 program is currently underway.
Researchers assessed the extent of which vaccine fatigue translates to reduced engagement and adherence among patients.
AJ Barbarito, Esq, explains how ERISA and Medicare Part D preemption limit state PBM laws and why a private right of action may be the most effective path forward.
Advertisement
Advertisement